Friday, January 06, 2012

Lilly's financial forecast in wake of Zyprexa patent loss is a downer for market | The Indianapolis Star |

Lilly also said that revenues would be between $21.8 billion and $22.8 billion, largely because of an expected loss of $3 billion in Zyprexa sales.

"This is a $500 million greater decline than we had forecast," Chris Schott, an analyst at J.P. Morgan, wrote in a research note. He called the updated guidance "disappointing" and a "top-line miss."

Posted via email from Jack's posterous

1 comment:

Daniel Haszard said...

Eli Lilly did make $41 billion on Zyprexa and they still expect to capture 20% of the US market as well as a billion year on ZyprexaXR.
The patent only expires in the US and some Euro,Lilly announced they have an *authorized* distributor of generic Zyprexa.
I am keenly interested in how they resolve remaining Zyprexa litigation.-Daniel Haszard